<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04244981</url>
  </required_header>
  <id_info>
    <org_study_id>PCC vs FFP Study</org_study_id>
    <nct_id>NCT04244981</nct_id>
  </id_info>
  <brief_title>Efficacy of Prothrombin Complex Concentrate Reducing Perioperative Blood Loss in Cardiac Surgery</brief_title>
  <official_title>Efficacy of Prothrombin Complex Concentrate Reducing Perioperative Blood Loss in Cardiac Surgery, Compared With Fresh Frozen Plasma: Study Protocol for a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences, Fuwai Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese Academy of Medical Sciences, Fuwai Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized, double-blinded, controlled clinical trial, based on the
      hypothesis that PCC reduces the allogeneic blood transfusion requirement relative to FFP in
      patients undergoing cardiac surgery under CPB. 180 subjects will be randomly divided into 2
      groups (group PCC and group FFP), with 90 cases in each group. Patients will be given a
      4-factor PCC based on the patients' body weight and INR in group PCC and a dose of 10-15
      ml/kg FFP in group FFP. All the patients will be followed up respectively at 24 hours, 48
      hours, 72 hours, 7 days and 30 days after the surgery. The primary outcome is the rate of
      allogeneic red blood cell (RBC) transfusion required during the intraoperative and
      postoperative period up to 7 days after surgery, and we want to explore the efficacy of PCC
      reducing perioperative blood loss and allogeneic blood transfusion in patients undergoing
      cardiac surgery under CPB, compared with FFP.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Perioperative blood loss and allogeneic blood transfusion are major complications of cardiac
      surgery, which increase perioperative complications, perioperative mortality and medical
      costs.This study is a randomized, double-blinded, controlled clinical trial, in order to
      determine whether PCC is more effective than FFP in reducing perioperative blood loss and
      allogeneic blood transfusion in patients undergoing cardiac surgery under CPB. Patients
      signed the informed consent, aged 18 to 80 years, receiving elective CABG or valve
      replacement or valvuloplasty under CPB in Fu Wai Hospital will be included. 180 subjects will
      be randomly divided into 2 groups (group PCC and group FFP), with 90 cases in each group.
      Preoperative management, anesthetic and surgical techniques will be standardized for both
      groups. When APTT is prolonged (&gt;1.5 times normal), patients will be given a 4-factor PCC
      based on the patients' body weight and INR (INR 2-4, PCC 25 IU/kg; INR 4-6, PCC 35 IU/kg;
      INR&gt;6, PCC 50 IU/kg) in group PCC and a dose of 10-15 ml/kg FFP in group FFP. All the
      patients will be followed up respectively at 24 hours, 48 hours, 72 hours, 7 days and 30 days
      after the surgery to record observations relevant to the study and the results of laboratory
      testing. The laboratory tests include hemoglobin concentration, hematocrit, platelet count,
      INR, PT, APTT, fibrinogen, serum glucose, creatinine, AST, and ALT concentrations. Blood loss
      is collected during the surgical procedure and within 48 hours after the surgery. The primary
      outcome is the rate of allogeneic red blood cell (RBC) transfusion required during the
      intraoperative and postoperative period up to 7 days after surgery. The secondary outcomes
      include (1) the total units of allogeneic RBC transfused during the intraoperative and
      postoperative period up to 7 days after surgery; (2) the volume of perioperative blood loss;
      (3) the rate of reexploration due to bleeding within 30 days after the surgery.
      Intent-to-treat analysis will be used for all the valid variables. Baseline characteristics
      will be tabulated shown and compared between PCC and FFP groups using standardized
      difference. The primary outcome will be compared using chi-square test and continuous
      secondary outcomes will be compared using t-test with log transformation of the variable. The
      use of postoperative hemostatic medications and reopening due to postoperative bleeding will
      be compared using chi-square test. Treatment effect will be measured by odds ratio and mean
      difference for binary and continuous outcomes with corresponding 95% confidence intervals. No
      correction for multiple comparison will be conducted in the analyses of the secondary
      outcomes, hence, the findings for secondary outcomes will be only interpreted as explanatory
      results. A two-sided P-value &lt; 0.05 is considered statistically significant.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2020</start_date>
  <completion_date type="Anticipated">October 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>180 patients who meet the criteria will be randomly divided into 2 groups, named prothrombin complex concentrate group (group PCC) and fresh frozen plasma group (control group, group FFP), with 90 cases in each group. Preoperative management, anesthetic and surgical techniques will be standardized for all patients. Prolonged APTT (&gt;1.5 times normal)34 will be regarded as a trigger for administration of PCC or FFP, according to the randomized groups. In group PCC, patients will be given a 4-factor PCC based on the patients' body weight and INR (INR 2-4, PCC 25 IU/kg; INR 4-6, PCC 35 IU/kg; INR&gt;6, PCC 50 IU/kg). In group FFP, patients will be given FFP based on the patients' body weight (10-15 mL/kg).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>This is a double-blind study with products masked and coded so that patients and care providers are unaware of which product each patient receiving. Anesthetic personnel not involved in patient care dispense the trial medicine for each patient.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>rate of perioperative allogeneic red blood cell (RBC) transfusion</measure>
    <time_frame>during the intraoperative and postoperative period up to 7 days after surgery</time_frame>
    <description>the rate of allogeneic red blood cell transfusion (RBC) required during the intraoperative and postoperative period up to 7 days after surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>total volume of perioperative allogeneic RBC transfusion</measure>
    <time_frame>during the intraoperative and postoperative period up to 7 days after surgery</time_frame>
    <description>the total units of allogeneic RBC transfused during the intraoperative and postoperative period up to 7 days after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>volume of perioperative blood loss</measure>
    <time_frame>during the intraoperative and postoperative period up to 48 hours after surgery</time_frame>
    <description>the volume of perioperative blood loss (i.e. chest drainage)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of reexploration due to bleeding</measure>
    <time_frame>within 30 days after the surgery</time_frame>
    <description>rate of reexploration due to bleeding</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Cardiac Surgical Procedures</condition>
  <arm_group>
    <arm_group_label>PCC group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>When APTT is prolonged (&gt;1.5 times normal), patients will be given a 4-factor PCC based on the patients' body weight and INR (INR 2-4, PCC 25 IU/kg; INR 4-6, PCC 35 IU/kg; INR&gt;6, PCC 50 IU/kg).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FFP group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>When APTT is prolonged (&gt;1.5 times normal), patients will be given a dose of 10-15 ml/kg FFP.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prothrombin Complex Concentrate, Human</intervention_name>
    <description>A 4-factor prothrombin complex concentrate (ConfidexÂ®, CSL Behring, Marburg, Germany), containing a defined concentration of the four vitamin K-dependent clotting factors (II, VII, IX and X) and the thrombo-inhibitor proteins C and S. Each vial of ConfidexÂ® contains a relatively high concentration of coagulation factor II (20-48 IU/mL), factor VII (10-25 IU/mL), factor IX (20-31 IU/mL), factor X (22-60 IU/mL), proteins C (15-45 IU/mL), proteins S (13-38 IU/mL), Heparin (0.5 IU/mL), and antithrombin (0.6 IU/mL). The administration is based on the patients' body weight and INR (INR 2-4, PCC 25 IU/kg; INR 4-6, PCC 35 IU/kg; INR&gt;6, PCC 50 IU/kg)</description>
    <arm_group_label>PCC group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fresh Frozen Plasma</intervention_name>
    <description>FFP will be given based on the patients' body weight (10-15 mL/kg).</description>
    <arm_group_label>FFP group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Receiving elective coronary artery bypass grafting (CABG), or valve replacement or
             valvuloplasty with cardiopulmonary bypass

          -  Sign the informed consent

        Exclusion Criteria:

          -  History of cardiac surgery

          -  With hepatic dysfunctions

          -  Serum creatinine higher than 176 umol/l

          -  Severe coagulopathy

          -  Withdraw clopidogrel or aspirin less than 7 days and low molecular heparin less than
             24 hours before surgery

          -  With hematological disorders

          -  Allergic to allogeneic blood products

          -  Pregnant

          -  With other serious diseases which may affect patients' survival time such as tumor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shi Jia, M.D.</last_name>
    <phone>86 10 88322467</phone>
    <email>shijia@fuwai.com</email>
  </overall_contact>
  <reference>
    <citation>Parr KG, Patel MA, Dekker R, Levin R, Glynn R, Avorn J, Morse DS. Multivariate predictors of blood product use in cardiac surgery. J Cardiothorac Vasc Anesth. 2003 Apr;17(2):176-81.</citation>
    <PMID>12698398</PMID>
  </reference>
  <reference>
    <citation>Moulton MJ, Creswell LL, Mackey ME, Cox JL, Rosenbloom M. Reexploration for bleeding is a risk factor for adverse outcomes after cardiac operations. J Thorac Cardiovasc Surg. 1996 May;111(5):1037-46.</citation>
    <PMID>8622301</PMID>
  </reference>
  <reference>
    <citation>Mariscalco G, Biancari F, Juvonen T, Zanobini M, Cottini M, Banach M, Murphy GJ, Beghi C, Angelini GD. Red blood cell transfusion is a determinant of neurological complications after cardiac surgery. Interact Cardiovasc Thorac Surg. 2015 Feb;20(2):166-71. doi: 10.1093/icvts/ivu360. Epub 2014 Nov 2.</citation>
    <PMID>25368133</PMID>
  </reference>
  <reference>
    <citation>Alfirevic A, Xu M, Johnston D, Figueroa P, Koch CG. Transfusion increases the risk for vasoplegia after cardiac operations. Ann Thorac Surg. 2011 Sep;92(3):812-9. doi: 10.1016/j.athoracsur.2011.04.020. Epub 2011 Jul 23.</citation>
    <PMID>21788009</PMID>
  </reference>
  <reference>
    <citation>Sellman M, Intonti MA, Ivert T. Reoperations for bleeding after coronary artery bypass procedures during 25 years. Eur J Cardiothorac Surg. 1997 Mar;11(3):521-7.</citation>
    <PMID>9105818</PMID>
  </reference>
  <reference>
    <citation>Ottino G, De Paulis R, Pansini S, Rocca G, Tallone MV, Comoglio C, Costa P, Orzan F, Morea M. Major sternal wound infection after open-heart surgery: a multivariate analysis of risk factors in 2,579 consecutive operative procedures. Ann Thorac Surg. 1987 Aug;44(2):173-9.</citation>
    <PMID>3619541</PMID>
  </reference>
  <reference>
    <citation>Zacharias A, Habib RH. Factors predisposing to median sternotomy complications. Deep vs superficial infection. Chest. 1996 Nov;110(5):1173-8.</citation>
    <PMID>8915216</PMID>
  </reference>
  <reference>
    <citation>Linden MD. The hemostatic defect of cardiopulmonary bypass. J Thromb Thrombolysis. 2003 Dec;16(3):129-47. Review.</citation>
    <PMID>15087599</PMID>
  </reference>
  <reference>
    <citation>Society of Thoracic Surgeons Blood Conservation Guideline Task Force, Ferraris VA, Ferraris SP, Saha SP, Hessel EA 2nd, Haan CK, Royston BD, Bridges CR, Higgins RS, Despotis G, Brown JR; Society of Cardiovascular Anesthesiologists Special Task Force on Blood Transfusion, Spiess BD, Shore-Lesserson L, Stafford-Smith M, Mazer CD, Bennett-Guerrero E, Hill SE, Body S. Perioperative blood transfusion and blood conservation in cardiac surgery: the Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists clinical practice guideline. Ann Thorac Surg. 2007 May;83(5 Suppl):S27-86. Review.</citation>
    <PMID>17462454</PMID>
  </reference>
  <reference>
    <citation>Dacey LJ, Munoz JJ, Baribeau YR, Johnson ER, Lahey SJ, Leavitt BJ, Quinn RD, Nugent WC, Birkmeyer JD, O'Connor GT. Reexploration for hemorrhage following coronary artery bypass grafting: incidence and risk factors. Northern New England Cardiovascular Disease Study Group. Arch Surg. 1998 Apr;133(4):442-7.</citation>
    <PMID>9565127</PMID>
  </reference>
  <reference>
    <citation>Despotis G, Eby C, Lublin DM. A review of transfusion risks and optimal management of perioperative bleeding with cardiac surgery. Transfusion. 2008 Mar;48(1 Suppl):2S-30S. doi: 10.1111/j.1537-2995.2007.01573.x. Review.</citation>
    <PMID>18302579</PMID>
  </reference>
  <reference>
    <citation>Karkouti K, Callum J, Crowther MA, McCluskey SA, Pendergrast J, Tait G, Yau TM, Beattie WS. The relationship between fibrinogen levels after cardiopulmonary bypass and large volume red cell transfusion in cardiac surgery: an observational study. Anesth Analg. 2013 Jul;117(1):14-22. doi: 10.1213/ANE.0b013e318292efa4. Epub 2013 May 17.</citation>
    <PMID>23687229</PMID>
  </reference>
  <reference>
    <citation>Weber CF, Klages M, Zacharowski K. Perioperative coagulation management during cardiac surgery. Curr Opin Anaesthesiol. 2013 Feb;26(1):60-4. doi: 10.1097/ACO.0b013e32835afd28. Review.</citation>
    <PMID>23222215</PMID>
  </reference>
  <reference>
    <citation>Khuri SF MA, Valeri CR. The effects of cardiopulmonary bypass on hemostasis. Loscabo J, Schafer AI, eds. Thrombosis &amp; Hemorrhage. Cambridge: Blackwell Science. 1993;1993:1051-1073.</citation>
  </reference>
  <reference>
    <citation>Kaspereit F, Hoffmann S, Pragst I, Dickneite G. Prothrombin complex concentrate mitigates diffuse bleeding after cardiopulmonary bypass in a porcine model. Br J Anaesth. 2010 Nov;105(5):576-82. doi: 10.1093/bja/aeq216. Epub 2010 Aug 17.</citation>
    <PMID>20716565</PMID>
  </reference>
  <reference>
    <citation>Bilgin YM, van de Watering LM, Versteegh MI, van Oers MH, Vamvakas EC, Brand A. Postoperative complications associated with transfusion of platelets and plasma in cardiac surgery. Transfusion. 2011 Dec;51(12):2603-10. doi: 10.1111/j.1537-2995.2011.03200.x. Epub 2011 Jun 3.</citation>
    <PMID>21645007</PMID>
  </reference>
  <reference>
    <citation>Society of Thoracic Surgeons Blood Conservation Guideline Task Force, Ferraris VA, Brown JR, Despotis GJ, Hammon JW, Reece TB, Saha SP, Song HK, Clough ER; Society of Cardiovascular Anesthesiologists Special Task Force on Blood Transfusion, Shore-Lesserson LJ, Goodnough LT, Mazer CD, Shander A, Stafford-Smith M, Waters J; International Consortium for Evidence Based Perfusion, Baker RA, Dickinson TA, FitzGerald DJ, Likosky DS, Shann KG. 2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. Ann Thorac Surg. 2011 Mar;91(3):944-82. doi: 10.1016/j.athoracsur.2010.11.078. Review.</citation>
    <PMID>21353044</PMID>
  </reference>
  <reference>
    <citation>Stanworth SJ, Brunskill SJ, Hyde CJ, McClelland DB, Murphy MF. Is fresh frozen plasma clinically effective? A systematic review of randomized controlled trials. Br J Haematol. 2004 Jul;126(1):139-52. Review.</citation>
    <PMID>15198745</PMID>
  </reference>
  <reference>
    <citation>Sun JC, Davidson MJ, Lamy A, Eikelboom JW. Antithrombotic management of patients with prosthetic heart valves: current evidence and future trends. Lancet. 2009 Aug 15;374(9689):565-76. doi: 10.1016/S0140-6736(09)60780-7. Review.</citation>
    <PMID>19683642</PMID>
  </reference>
  <reference>
    <citation>Eitz T, Schenk S, Fritzsche D, Bairaktaris A, Wagner O, Koertke H, Koerfer R. International normalized ratio self-management lowers the risk of thromboembolic events after prosthetic heart valve replacement. Ann Thorac Surg. 2008 Mar;85(3):949-54; discussion 955. doi: 10.1016/j.athoracsur.2007.08.071.</citation>
    <PMID>18291177</PMID>
  </reference>
  <reference>
    <citation>Safaoui MN, Aazami R, Hotz H, Wilson MT, Margulies DR. A promising new alternative for the rapid reversal of warfarin coagulopathy in traumatic intracranial hemorrhage. Am J Surg. 2009 Jun;197(6):785-90. doi: 10.1016/j.amjsurg.2008.04.003. Epub 2008 Aug 22.</citation>
    <PMID>18722586</PMID>
  </reference>
  <reference>
    <citation>Demeyere R, Gillardin S, Arnout J, Strengers PF. Comparison of fresh frozen plasma and prothrombin complex concentrate for the reversal of oral anticoagulants in patients undergoing cardiopulmonary bypass surgery: a randomized study. Vox Sang. 2010 Oct;99(3):251-60. doi: 10.1111/j.1423-0410.2010.01339.x.</citation>
    <PMID>20840339</PMID>
  </reference>
  <reference>
    <citation>Wallace EL. Monitoring the nation's blood supply. Transfusion. 2003 Mar;43(3):299-301.</citation>
    <PMID>12675711</PMID>
  </reference>
  <reference>
    <citation>Kakkar N, Kaur R, Dhanoa J. Improvement in fresh frozen plasma transfusion practice: results of an outcome audit. Transfus Med. 2004 Jun;14(3):231-5.</citation>
    <PMID>15180815</PMID>
  </reference>
  <reference>
    <citation>Fariborz Farsad B, Golpira R, Najafi H, Totonchi Z, Salajegheh S, Bakhshandeh H, Hashemian F. Comparison between Prothrombin Complex Concentrate (PCC) and Fresh Frozen Plasma (FFP) for the Urgent Reversal of Warfarin in Patients with Mechanical Heart Valves in a Tertiary Care Cardiac Center. Iran J Pharm Res. 2015 Summer;14(3):877-85.</citation>
    <PMID>26330876</PMID>
  </reference>
  <reference>
    <citation>Cromwell C, Aledort LM. FEIBA: a prohemostatic agent. Semin Thromb Hemost. 2012 Apr;38(3):265-7. doi: 10.1055/s-0032-1309286. Epub 2012 Mar 29. Review.</citation>
    <PMID>22460908</PMID>
  </reference>
  <reference>
    <citation>Franchini M, Lippi G. Prothrombin complex concentrates: an update. Blood Transfus. 2010 Jul;8(3):149-54. doi: 10.2450/2010.0149-09. Review.</citation>
    <PMID>20671873</PMID>
  </reference>
  <reference>
    <citation>Hellstern P. Production and composition of prothrombin complex concentrates: correlation between composition and therapeutic efficiency. Thromb Res. 1999 Aug 15;95(4 Suppl 1):S7-12. Review.</citation>
    <PMID>10499903</PMID>
  </reference>
  <reference>
    <citation>Cappabianca G, Mariscalco G, Biancari F, Maselli D, Papesso F, Cottini M, Crosta S, Banescu S, Ahmed AB, Beghi C. Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery. Crit Care. 2016 Jan 6;20:5. doi: 10.1186/s13054-015-1172-6.</citation>
    <PMID>26738468</PMID>
  </reference>
  <reference>
    <citation>Song HK, Tibayan FA, Kahl EA, Sera VA, Slater MS, Deloughery TG, Scanlan MM. Safety and efficacy of prothrombin complex concentrates for the treatment of coagulopathy after cardiac surgery. J Thorac Cardiovasc Surg. 2014 Mar;147(3):1036-40. doi: 10.1016/j.jtcvs.2013.11.020. Epub 2013 Dec 22.</citation>
    <PMID>24365268</PMID>
  </reference>
  <reference>
    <citation>Weinberger J, Cipolle M. Optimal Reversal of Novel Anticoagulants in Trauma. Crit Care Clin. 2017 Jan;33(1):135-152. doi: 10.1016/j.ccc.2016.08.005. Review.</citation>
    <PMID>27894493</PMID>
  </reference>
  <reference>
    <citation>Ortmann E, Besser MW, Sharples LD, Gerrard C, Berman M, Jenkins DP, Klein AA. An exploratory cohort study comparing prothrombin complex concentrate and fresh frozen plasma for the treatment of coagulopathy after complex cardiac surgery. Anesth Analg. 2015 Jul;121(1):26-33. doi: 10.1213/ANE.0000000000000689.</citation>
    <PMID>25822921</PMID>
  </reference>
  <reference>
    <citation>Kozek-Langenecker SA, Afshari A, Albaladejo P, Santullano CA, De Robertis E, Filipescu DC, Fries D, GÃ¶rlinger K, Haas T, Imberger G, Jacob M, LancÃ© M, Llau J, Mallett S, Meier J, Rahe-Meyer N, Samama CM, Smith A, Solomon C, Van der Linden P, WikkelsÃ¸ AJ, Wouters P, Wyffels P. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol. 2013 Jun;30(6):270-382. doi: 10.1097/EJA.0b013e32835f4d5b. Review. Erratum in: Eur J Anaesthesiol. 2014 Apr;31(4):247.</citation>
    <PMID>23656742</PMID>
  </reference>
  <reference>
    <citation>Patanwala AE, Acquisto NM, Erstad BL. Prothrombin complex concentrate for critical bleeding. Ann Pharmacother. 2011 Jul;45(7-8):990-9. doi: 10.1345/aph.1Q096. Epub 2011 Jul 5. Review.</citation>
    <PMID>21730276</PMID>
  </reference>
  <reference>
    <citation>Biancari F, Ruggieri VG, Perrotti A, Gherli R, Demal T, Franzese I, DalÃ©n M, Santarpino G, Rubino AS, Maselli D, Salsano A, Nicolini F, Saccocci M, Gatti G, Rosato S, D'Errigo P, Kinnunen EM, De Feo M, Tauriainen T, Onorati F, Mariscalco G. Comparative Analysis of Prothrombin Complex Concentrate and Fresh Frozen Plasma in Coronary Surgery. Heart Lung Circ. 2019 Dec;28(12):1881-1887. doi: 10.1016/j.hlc.2018.10.025. Epub 2018 Dec 11.</citation>
    <PMID>30709591</PMID>
  </reference>
  <reference>
    <citation>Hellstern P, Halbmayer WM, KÃ¶hler M, Seitz R, MÃ¼ller-Berghaus G. Prothrombin complex concentrates: indications, contraindications, and risks: a task force summary. Thromb Res. 1999 Aug 15;95(4 Suppl 1):S3-6.</citation>
    <PMID>10499902</PMID>
  </reference>
  <reference>
    <citation>Huttner HB, Schellinger PD, Hartmann M, KÃ¶hrmann M, Juettler E, Wikner J, Mueller S, Meyding-Lamade U, Strobl R, Mansmann U, Schwab S, Steiner T. Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates. Stroke. 2006 Jun;37(6):1465-70. Epub 2006 May 4.</citation>
    <PMID>16675739</PMID>
  </reference>
  <reference>
    <citation>Erber WN, Perry DJ. Plasma and plasma products in the treatment of massive haemorrhage. Best Pract Res Clin Haematol. 2006;19(1):97-112. Review.</citation>
    <PMID>16377544</PMID>
  </reference>
  <reference>
    <citation>ViguÃ© B, Ract C, Tremey B, Engrand N, Leblanc PE, Decaux A, Martin L, Benhamou D. Ultra-rapid management of oral anticoagulant therapy-related surgical intracranial hemorrhage. Intensive Care Med. 2007 Apr;33(4):721-5. Epub 2007 Jan 27.</citation>
    <PMID>17260127</PMID>
  </reference>
  <reference>
    <citation>Levy JH, Tanaka KA, Dietrich W. Perioperative hemostatic management of patients treated with vitamin K antagonists. Anesthesiology. 2008 Nov;109(5):918-26. doi: 10.1097/ALN.0b013e3181895bd8. Review.</citation>
    <PMID>18946305</PMID>
  </reference>
  <reference>
    <citation>Leissinger CA, Blatt PM, Hoots WK, Ewenstein B. Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature. Am J Hematol. 2008 Feb;83(2):137-43. Review.</citation>
    <PMID>17729241</PMID>
  </reference>
  <reference>
    <citation>Bux J. Transfusion-related acute lung injury (TRALI): a serious adverse event of blood transfusion. Vox Sang. 2005 Jul;89(1):1-10. Review.</citation>
    <PMID>15938734</PMID>
  </reference>
  <reference>
    <citation>Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008 Jun;133(6 Suppl):160S-198S. doi: 10.1378/chest.08-0670.</citation>
    <PMID>18574265</PMID>
  </reference>
  <reference>
    <citation>Pabinger I, Brenner B, Kalina U, Knaub S, Nagy A, Ostermann H; Beriplex P/N Anticoagulation Reversal Study Group. Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. J Thromb Haemost. 2008 Apr;6(4):622-31. doi: 10.1111/j.1538-7836.2008.02904.x. Epub 2008 Jan 15.</citation>
    <PMID>18208533</PMID>
  </reference>
  <reference>
    <citation>Pabinger-Fasching I. Warfarin-reversal: results of a phase III study with pasteurised, nanofiltrated prothrombin complex concentrate. Thromb Res. 2008;122 Suppl 2:S19-22. doi: 10.1016/S0049-3848(08)70005-7. Review.</citation>
    <PMID>18549908</PMID>
  </reference>
  <reference>
    <citation>Nienaber U, Innerhofer P, Westermann I, SchÃ¶chl H, Attal R, Breitkopf R, Maegele M. The impact of fresh frozen plasma vs coagulation factor concentrates on morbidity and mortality in trauma-associated haemorrhage and massive transfusion. Injury. 2011 Jul;42(7):697-701. doi: 10.1016/j.injury.2010.12.015. Epub 2011 Mar 9.</citation>
    <PMID>21392760</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 5, 2020</study_first_submitted>
  <study_first_submitted_qc>January 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 28, 2020</study_first_posted>
  <last_update_submitted>February 28, 2020</last_update_submitted>
  <last_update_submitted_qc>February 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences, Fuwai Hospital</investigator_affiliation>
    <investigator_full_name>SHI Jia</investigator_full_name>
    <investigator_title>Vice Chair, the department of Anesthesiology</investigator_title>
  </responsible_party>
  <keyword>prothrombin complex concentrate</keyword>
  <keyword>fresh frozen plasma</keyword>
  <keyword>perioperative blood loss</keyword>
  <keyword>efficacy</keyword>
  <keyword>cardiac surgery</keyword>
  <keyword>cardiopulmonary bypass</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

